Lyka Labs (Small Cap - Next Multibagger) Share Target 2025, 2026 To 2035
|
Lyka Labs Limited |
|||
|
Price: ₹162.12 (+3.25%) | ||
| 52 Week Low: ₹97.90 52 Week High: ₹176.59 |
|||
| Market Capital: 504.4 Crore (Smallcap) | |||
| Healthcare -> Biotechnology | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Lyka Labs Share Price Target For 2025
- 1.1.1: Lyka Labs Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Lyka Labs Share Price Target For 2026
- 1.2.1: Lyka Labs Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Lyka Labs Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Lyka Labs Brief Company Overview
- 4: Lyka Labs Financial Performance
- 4.0.1: Is Lyka Labs A Good Buy For Long Term?
To predict the Lyka Labs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Lyka Labs Share Price Target For 2025
The line chart displays the monthly closing prices of Lyka Labs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lyka Labs shares in 2025, see the table below.
Lyka Labs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 180.69 (+11.45%) | Fibonacci Extension Level 23.60% |
| 2025 Target 2 | 176.59 (+8.92%) | Fibonacci Extension Level 100.00% |
| 2025 Target 1 | 174.8 (+7.82%) | Price Action: 05 Dec 2024 High |
| Current Price | 162.12 | Lyka Labs's share price as of 02 Jan 2025 |
| Stop Loss 1 | 156.5 (-3.47%) | Price Action: 27 Dec 2024 High |
| Stop Loss 2 | 154.7 (-4.58%) | Price Action: 24 Sep 2024 High |
| Stop Loss 3 | 153.06 (-5.59%) | Price Action: 14 Oct 2024 High |
Short-Term Technical Outlook
Current Technical Position: Lyka Labs is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹159.72 serves as the nearest technical reference point.
Historical Returns: 3-month: +11.77% | 6-month: +34.47% | 1-year: +33.97%
Lyka Labs Share Price Target For 2026
The line chart displays the monthly closing prices of Lyka Labs with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lyka Labs shares in 2026, see the table below.
Lyka Labs Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 225.69 (+39.21%) | Price Action: Chart |
| 2026 Target 2 | 221.48 (+36.61%) | Price Action: Chart |
| 2026 Target 1 | 219.29 (+35.26%) | Fibonacci Extension Level 64.90% |
| Current Price | 162.12 | Lyka Labs's share price as of 02 Jan 2025 |
| Stop Loss 1 | 149.05 (-8.07%) | Price Action: 24 Sep 2024 Low |
| Stop Loss 2 | 147.5 (-9.02%) | Price Action: Jan 1995 High |
| Stop Loss 3 | 146.0 (-9.94%) | Price Action: 03 Sep 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Lyka Labs is currently trading near its 52-week high of ₹176.59, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +33.97% | 3-year: -5.66% | 5-year: +683.19%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Lyka Labs Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹162.12 | ||
| 2025 | ₹163.65 | +0.94% | ₹166.10 |
| 2026 | ₹219.78 | +34.29% | ₹223.08 |
| 2027 | ₹246.22 | +12.03% | ₹249.91 |
| 2028 | ₹332.15 | +34.89% | ₹337.13 |
| 2029 | ₹362.50 | +9.13% | ₹367.94 |
| 2030 | ₹429.85 | +18.57% | ₹436.30 |
| 2031 | ₹488.95 | +13.74% | ₹496.28 |
| 2032 | ₹565.61 | +15.67% | ₹574.09 |
| 2033 | ₹690.74 | +22.12% | ₹701.10 |
| 2034 | ₹850.06 | +23.06% | ₹862.81 |
| 2035 | ₹831.56 | -2.17% | ₹844.03 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Lyka Labs Brief Company Overview
Lyka Labs Limited: A Leading Pharmaceutical Company in India Lyka Labs Limited, established in 1976, is a renowned pharmaceutical company based in Mumbai, India. The company has made a significant mark in the industry with its diverse product range and commitment to...
providing high-quality healthcare solutions. Lyka Labs specializes in developing, manufacturing, and marketing a wide array of pharmaceutical formulations and active pharmaceutical ingredients. Its product portfolio includes various therapeutic segments, including dermatological, pain management, anti-aging, anti-infective, and critical care. The company's commitment to innovation is evident in its impressive product range, which includes injections, creams, ointments, foams, gels, and lotions. Lyka Labs also provides contracted manufacturing services to leading pharmaceutical companies and offers medical and technical assistance in manufacturing processes. Lyka Labs Limited has a strong market presence across India and exports its products globally. The company's reputation for quality, reliability, and customer-centric approach has earned it a loyal customer base and a strong position in the industry.Lyka Labs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 504.4 Crore | Market valuation of Lyka Labs's shares. |
| Revenue (TTM) | 113.42 Crore | Total revenue generated by Lyka Labs over the past twelve months. |
| Net Income (TTM) | +68.88 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +6.47% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +0.7% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+31.6% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
86.1 | Company's total debt divided by total shareholder equity. |
| Total Debt | 58.78 Crore | Sum of Lyka Labs's current & long-term financial obligations. |
| Total Cash | 6.29 Crore | Total amount of liquid funds available to Lyka Labs. |
| Beta | 1.1 | Beta is greater than 1 indicating that the Lyka Labs's price is more volatile than the market. |
Is Lyka Labs A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
